Methods and Findings in Experimental and Clinical Pharmacology 1998-03-01

Paclitaxel, bropirimine and linomide: effect on growth inhibition in a murine prostate cancer model by different growth regulatory mechanisms.

M Shaw, S Ratanawong, P Chou, V Ray, Y Mirochnik, L Slobodskoy, M Rubenstein, P Guinan

Index: Methods Find. Exp. Clin. Pharmacol. 20(2) , 111-4, (1998)

Full Text: HTML

Abstract

Paclitaxel, bropirimine and linomide therapy was evaluated in a murine prostate cancer model. All drugs were effective in impeding tumor growth but the mechanisms of action varied. Paclitaxel inhibited bcl-2 expression suggesting an apoptotic mechanism. Bropirimine, while inhibiting bcl-2 expression also significantly depressed tumor necrosis factor-alpha (TNF-alpha) expression. In the bropirimine treated group there was also a correlation between angiogenesis and cyclin D expression. Finally, linomide significantly decreased angiogenesis. Since the mechanism of action of these drugs differ, combining them at lower doses might maintain therapeutic efficacy while reducing toxicity.